相关实验视频
Updated: May 15, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
一个新的化陶氏构造器涉及到人类神经元的陶氏病变病原体
Nahid Tofigh1,2, Sadaf Agahi3, Gholamhossein Riazi1
1Laboratory of Neuro-Organic Chemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran 13561-457, Iran.
Biomolecules
|April 30, 2025
概括
研究人员在阿尔茨海默氏症 (AD) 神经元中发现了一种新的有毒tau蛋白形状,左侧pT231-tau对应体. 消除这种符合性降低了神经退行,这表明它是阿尔茨海默病的有希望的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,没有有效的治疗方法.
- 蛋白的过酸化是关键的病理特征,有助于AD的神经退行.
- 之前的研究已经确定了pT231-tau的cis形状是神经退行症的早期驱动因素.
研究的目的:
- 在人类阿尔茨海默氏症 (AD) 神经元中识别新的有毒tau蛋白适配体.
- 调查与衰老相关的压力的作用在特定的陶氏基因对象的积累.
- 评估针对AD中新发现的tau适应体的治疗潜力.
主要方法:
- 在人类AD神经元中使用先进的生物化学技术识别和表征新型tau蛋白对应物.
- 在衰老压力下的人类诱导多能干细胞 (iPSC) 衍生和小鼠皮质神经元中p21积累的评估.
- 在人类AD培养物中实验性消除已识别的新型tau符合者,以评估其对神经退行症的影响.
主要成果:
- 在人类AD神经元中发现了一种新的神经毒性pT231-tau适应体,称为左侧pT231-tau适应体.
- 在遭受老化相关压力的神经元中,左侧pT231-tau符合者的水平升高.
- 针对性地消除左侧的pT231-tau对应物显著减轻了人类AD文化中的神经退行.
结论:
- 左边的pT231-tau符合者是一个独特的,神经毒性物种,涉及阿尔茨海默氏症的病原性.
- 与衰老相关的压力有助于这种有毒的陶氏体的积累.
- 针对左侧的pT231-tau适配器代表了对阿尔茨海默病的潜在治疗策略.
相关概念视频
Phosphorylation
49.5K
The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
49.5K
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Protein Kinases and Phosphatases
12.9K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
12.9K
Enzyme-linked Receptors
76.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
76.5K

